Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010629 · ClinicalTrials.gov registry record · Phase 2
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
A Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05010629: Active Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
NCT05010629 is a Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma that is active but no longer recruiting, run by Glenn J. Hanna. The registered enrollment target is 35 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05010629, a Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma, is active but no longer recruiting, sponsored by Glenn J. Hanna.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
Primary Outcome
ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and a
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG 9-ING-41
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2027-04-12 |
| Phase | Phase 2 |
What the registry record for NCT05010629 still lists
NCT05010629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT05010629 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05010629 about?
NCT05010629 is a clinical study titled "9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma". This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
What is the current status of trial NCT05010629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2021-09-14. Estimated completion is 2027-04-12.
What conditions does trial NCT05010629 study?
This clinical trial studies the following conditions: Metastatic Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Recurrent Salivary Gland Cancer.
What interventions are being tested in trial NCT05010629?
The interventions under investigation include: Carboplatin (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT05010629?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010629 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05010629's enrollment target sits among peer trials
35 76th of 109 higher than 33 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI